Showing results (171-180 of 303) with videos related to
Sort By:
Pageof 31
Biochimica Et Biophysica Acta|December 1, 2015
Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: Role of PPARγJinbiao Chen, Wei Wang, Yanfei Qi, et al.Journal of Hepatology|December 28, 2010
Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitisLisa Lo, Susan V McLennan, Paul F Williams, et al.Transplant Immunology|August 25, 2012
Expression of common gamma chain signalling cytokines and their receptors distinguishes rejection from tolerance in a rat organ transplant modelAnar Ganbold, Sean Andersen, Szun S Tay, et al.Journal of Clinical Gastroenterology|December 17, 2004
The direct cost of managing patients with chronic hepatitis B infection in AustraliaJames R G Butler, Stephen Pianko, Rosemary J Korda, et al.Transplantation|May 10, 2005
Posttransplant interleukin-4 treatment converts rat liver allograft tolerance to rejectionChuanmin Wang, Jian Li, Shaun P Cordoba, et al.Transplantation|May 14, 2008
Blocking indoleamine dioxygenase activity early after rat liver transplantation prevents long-term survival but does not cause acute rejectionJerome M Laurence, Chuanmin Wang, Euiyoun T Park, et al.Biochimica Et Biophysica Acta. Molecular Basis of Disease|January 1, 2022
Deletion of kif3a in CK19 positive cells leads to primary cilia loss, biliary cell proliferation and cystic liver lesions in TAA-treated miceJinbiao Chen, Ngan Ching Cheng, Jade A Boland, et al.International Journal of Molecular Sciences|May 30, 2014
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and developmentThomas Tu, Magdalena A Budzinska, Annette E Maczurek, et al.Hepatology (Baltimore, Md.)|May 4, 2004
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability indexArchana Sud, Jason M Hui, Geoffrey C Farrell, et al.Frontiers in Immunology|October 5, 2023
Novel miRNA-based drug CD5-2 reduces liver tumor growth in diethylnitrosamine-treated mice by normalizing tumor vasculature and altering immune infiltrateKen Liu, Jinbiao Chen, Yang Zhao, et al.Pageof 31